Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory

Area of Science:

• Oncology
• Microbiology
• Pharmacology

Background:

• Cancer stem cells (CSCs) are key drivers of tumor initiation, metastasis, and therapeutic resistance.
• Understanding CSC biology and their distinct molecular pathways is crucial for developing effective cancer treatments.
• The gut microbiota plays a significant role in cancer development and response to therapy.

Purpose of the Study:

• To review the role of CSCs in tumor biology and therapy resistance.
• To explore the influence of gut microbiota in cancer development and treatment.
• To discuss advances in identifying microbiota-derived natural compounds that target CSCs.

Main Methods:

• Literature review of CSC biology, therapy resistance mechanisms, and gut microbiota roles.
• Analysis of current research on natural compounds derived from gut microbes targeting CSCs.
• Discussion of potential therapeutic strategies involving microbiota-derived compounds.

Main Results:

• CSCs possess unique molecular pathways that can be exploited for targeted therapies.
• Gut microbiota can influence cancer progression and treatment outcomes.
• Several microbial metabolites show potential in suppressing CSC properties and enhancing chemotherapy.

Conclusions:

• Targeting CSCs by inhibiting stemness is a promising strategy to combat cancer recurrence and metastasis.
• Microbiota-derived natural compounds represent a novel therapeutic avenue for CSC-targeted cancer treatment.
• Dietary interventions promoting beneficial microbial metabolites could support standard chemotherapy regimens.